Stockscreener 앱 받기
2.71
1.45%
-0.04
시장 영업 전:
2.56
-0.15
-5.54%
전일 마감가:
$2.75
열려 있는:
$2.51
하루 거래량:
306.35K
Relative Volume:
0.53
시가총액:
$2.88M
수익:
-
순이익/손실:
$-11.91M
주가수익비율:
-0.3057
EPS:
-8.8661
순현금흐름:
$-10.83M
1주 성능:
-35.01%
1개월 성능:
-6.23%
6개월 성능:
-89.62%
1년 성능:
-97.85%
1일 변동 폭
$2.33
$2.775
1주일 범위
$2.33
$3.98
52주 변동 폭
$2.31
$223.60
Silexion Therapeutics Corp Stock (SLXN) Company Profile
명칭
Silexion Therapeutics Corp
전화
972-8-6286005
주소
12 ABBA HILLEL ROAD, RAMAT GAN
Compare SLXN vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
SLXN
Silexion Therapeutics Corp
|
2.71 | 2.92M | 0 | -11.91M | -10.83M | -8.8661 |
VRTX
Vertex Pharmaceuticals Inc
|
453.17 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
614.73 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
878.49 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
281.90 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
156.58 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Silexion Therapeutics Corp 주식(SLXN)의 최신 뉴스
SLXN Q1 2026 Earnings: Narrowed Loss Beats Estimates with 35.4% EPS SurpriseAnalyst Drop Coverage - newsline.com
Silexion Therapeutics (NASDAQ: SLXN) registers up to 859,609 resale shares - Stock Titan
Silexion Therapeutics Warrants (SLXNW) Plunge 33% as Support at $0.03 Faces TestValue Factor - newsline.com
Silexion Therapeutics Corp Ord Stock Short Interest Falls to 43.76% - Quiver Quantitative
SLXN Q1 2026 Earnings: Narrowed Loss Per Share Surprises, Stock GainsCapex Guidance - newsline.com
Number of shareholders of Silexion Therapeutics Corp – NASDAQ:SLXN - TradingView
Silexion (SLXN) awards CSO 6,000 RSUs after reverse share split - Stock Titan
[Form 4] Silexion Therapeutics Corp Insider Trading Activity - Stock Titan
Silexion (SLXN) CEO granted 10,000 shares; holdings rise to 16,547 - Stock Titan
Silexion Therapeutics Corp (SLXN) Q1 2026 Earnings: Narrower-Than-Expected Loss as Clinical Pipeline ProgressesGross Profit Margin - newsline.com
Number of shareholders of Silexion Therapeutics Corp – NASDAQ:SLXNW - TradingView
Silexion (SLXN) asks shareholders to OK 399,020 warrants and a capital increase - Stock Titan
Silexion Stock Just Split 1-for-10. The Real Test Starts Now - Bez Kabli
Silexion Therapeutics Implements 1-for-10 Reverse Share Split - The Globe and Mail
Moringa (SLXN) discloses 1,382,346-share Silexion stake and contests note issuances - Stock Titan
- newsline.com
Silexion Therapeutics Corp Files Form 8-K: NASDAQ Listing, Company Details, and Warrant Information - Minichart
Silexion Therapeutics (SLXN) completes 1-for-10 reverse split, adjusts warrant terms - Stock Titan
SLXN Q1 2026 Earnings: Narrower-Than-Expected Loss Signals Cost DisciplinePreliminary Results - thelegaladvocate.com
Silexion Therapeutics announces 1-for-10 reverse share split - MSN
Silexion Therapeutics (SLXN) Slips 3% as Shares Test Key Support at $0.40Shakeout Pattern - thelegaladvocate.com
Silexion Therapeutics Corp Warrant (SLXNW) Faces Continued Selling Pressure at Penny LevelRevenue Weighted - newsline.com
Silexion Therapeutics Announces Reverse Split to Maintain Listing - The Globe and Mail
SLXN Q1 2026 Earnings: Narrower-Than-Expected Loss Highlights Cost DisciplineWeak Earnings Momentum - newsline.com
Silexion Therapeutics Begins GMP Manufacturing of SIL204 and Receives Approval for Phase 2/3 Trial at Tel Aviv Sourasky Medical Center - geneonline.com
Silexion announces 1-for-10 reverse stock split effective Thursday By Investing.com - Investing.com Australia
Silexion Therapeutics Announces 1-For-10 Reverse Share Split - TradingView
Silexion announces 1-for-10 reverse stock split effective Thursday - Investing.com
Silexion Therapeutics to implement 1-for-10 reverse share split, effective May 29, 2026 - TradingView
Silexion (NASDAQ: SLXN) plans 1-for-10 reverse share split to aid Nasdaq compliance - Stock Titan
Silexion Therapeutics Announces 1-for-10 Reverse Share Split - Moomoo
Silexion Therapeutics Corp Warrant (SLXNW) Struggles Near $0.02: Low Volume and Narrow Trading RangeMutual Fund Flow - newsline.com
Silexion Therapeutics (SLXN) Q1 2026 Earnings: Narrower-Than-Expected Loss Drives Positive Stock ReactionCore Business Growth - newsline.com
Silexion Therapeutics (SLXN): Modest Gains as Stock Holds Key Support at $0.46Percent Above MA - Newser
SLXN Q1 2026 Earnings: Narrower-Than-Expected Loss Drives Surprise but Stock DeclinesFinal Results - newsline.com
Silexion Therapeutics prices new warrants exercise deal at $0.50 to raise $1M - MSN
Silexion Therapeutics Stock Surges 97% on Phase 2/3 Trial Approval - Meyka
Silexion Soars After Cancer Study, Liquidity and Nasdaq Issues Linger for SLXN - TechStock²
Silexion Therapeutics(SLXN) Stock Options Chain | Quotes & News - Moomoo
Biotech Stock Silexion Therapeutics Corp. (NASDAQ: SLXN) Soars on Update and First Quarter Results - Investorideas.com
Silexion Therapeutics (SLXN) spikes as investors react to mid-May clinical-trial milestones and fresh financing - Quiver Quantitative
Silexion’s Cancer Trial Push Puts Focus on Cash - TechStock²
Silexion Therapeutics Posts Wider Q1 Loss, Advances SIL204 Into Phase 2/3 Trials; Stock Up - RTTNews
Silexion Therapeutics (SLXN) Gained +56.13% — Can It Break $0.44? 2026-05-20MAMA Signal - Newser
Silexion (NASDAQ: SLXN) 10-K amendment corrects internal control date - Stock Titan
Silexion Therapeutics Corp (SLXN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.27%
1.43%
자본화:
|
볼륨(24시간):